University Health Network

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 10K

Market Cap: -

Website: http://www.uhn.ca

Clinical Trials

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Neoadjuvant Treatment
Debulking Surgical Procedures

Interventions: Drug: Olaparib
Drug: Platinum-based Chemotherapy

First Posted Date: 2015-07-02

Last Posted Date: 2024-01-17

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 71

Registration Number: NCT02489006

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
Centre hospitalier de l'Université de Montréal (CHUM, Montréal, Quebec, Canada
🇨🇦
Jewish General Hospital, Montréal, Quebec, Canada

and more 6 locations

A Study of Long-Term Responders on Olaparib

Completed

Conditions: Fallopian Tube Cancer
Epithelial Ovarian Cancer
Peritoneal Cancer

First Posted Date: 2015-07-02

Last Posted Date: 2023-01-10

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 118

Registration Number: NCT02489058

Locations: 🇦🇺
South Eastern Sydney Local Health District, Randwick, New South Wales, Australia
🇨🇦
British Columbia Cancer Centre, Vancouver, British Columbia, Canada
🇪🇸
Vall d'Hebron, Barcelona, Spain

and more 5 locations

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: IL-12

First Posted Date: 2015-06-26

Last Posted Date: 2025-02-03

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 9

Registration Number: NCT02483312

Locations: 🇨🇦
Princess Margaret Centre Centre, Toronto, Ontario, Canada

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Phase 1

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Radiation: Radiation Therapy
Procedure: Surgical Resection

First Posted Date: 2015-06-25

Last Posted Date: 2024-07-17

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 30

Registration Number: NCT02481635

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)

Phase 3

Terminated

Conditions: Hepatitis C Viral Infection

Interventions: Drug: Sofosbuvir (SOF) and Ledipasvir (LDV)

First Posted Date: 2015-06-23

Last Posted Date: 2016-08-08

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT02478229

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation

Phase 1

Conditions: End-stage Liver Disease

Interventions: Device: OrganOx Metra

First Posted Date: 2015-06-23

Last Posted Date: 2022-04-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 40

Registration Number: NCT02478151

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging

Not Applicable

Completed

Conditions: Head and Neck Neoplasms

Interventions: Procedure: Sentinel lymph node mapping
Drug: Indocyanine Green (ICG)
Device: near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)

First Posted Date: 2015-06-23

Last Posted Date: 2024-04-15

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 1

Registration Number: NCT02478138

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

Phase 2

Withdrawn

Conditions: Psoriatic Arthritis
Impaired Glucose Tolerance
Psoriasis
Type 2 Diabetes

Interventions: Other: Placebo
Drug: liraglutide

First Posted Date: 2015-06-16

Last Posted Date: 2017-07-17

Lead Sponsor: University Health Network, Toronto

Registration Number: NCT02472717

Locations: 🇨🇦
Toronto Western Hospital, The Centre for Prognosis Studies in the Rheumatic Diseases (CPSRD), University of Toronto, Toronto, Ontario, Canada

The Use of Botox in Advanced Parkinson's Patients Experiencing Pain

Phase 4

Conditions: Parkinson's Disease

Interventions: Drug: Botulinum Toxin

First Posted Date: 2015-06-15

Last Posted Date: 2015-06-26

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 14

Registration Number: NCT02472210

Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC

Phase 4

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: CT perfusion
Drug: Norepinephrine intra-arteriel/hepatic

First Posted Date: 2015-06-15

Last Posted Date: 2021-04-28

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 10

Registration Number: NCT02472249

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy